Market Opportunity HilleVax is developing HIL-214, a novel vaccine for preventing norovirus-related acute gastroenteritis. Engaging with healthcare providers and institutions focusing on gastroenterology could be a strategic sales opportunity.
Partnership Potential HilleVax collaborated with Kangh to develop a groundbreaking norovirus vaccine. Exploring partnerships with other biotech companies or pharmaceutical distributors for joint marketing and distribution efforts can extend market reach.
Key Personnel Transition HilleVax recently appointed Sean McLoughlin as the Chief Operating Officer and Dr. Aditya Kohli as the Chief Business Officer. Leveraging these new leadership positions for networking and partnership opportunities within the healthcare industry could lead to sales growth.
Competitive Positioning HilleVax faces competition from established companies like Walgreens, CVS Health, and Kaiser Permanente in the healthcare sector. Identifying unique selling points and emphasizing HIL-214's efficacy and innovation can help differentiate the product in a competitive market.
Financial Stability With a revenue range of $10M - $50M and funding of $100M, HilleVax demonstrates financial stability. Highlighting this financial backing to potential investors and partners can build confidence in the company's growth potential, facilitating sales conversations.
86K
$1B
49K$1B
120K$1B
122K$1B
83$10M$50M
445K$1B
1K$100M$1BHilleVax uses 8 technology products and services including SAS, Google Font API, ADP HRMS, and more. Explore HilleVax's tech stack below.
| HilleVax Email Formats | Percentage |
| FLast@hillevax.com | 49% |
| LastF@hillevax.com | 1% |
| FLast@hillevax.com | 49% |
| LastF@hillevax.com | 1% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Company Overview
Media & News
Funding & FinancialsHilleVax has raised a total of $100M of funding over 2 rounds. Their latest funding round was raised on Sep 19, 2023 in the amount of $100M.
HilleVax's revenue is in the range of $10M$50M
Funding & FinancialsHilleVax has raised a total of $100M of funding over 2 rounds. Their latest funding round was raised on Sep 19, 2023 in the amount of $100M.
HilleVax's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com